TrialCritical care (London, England)2023

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.

Marius Trøseid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.